Eli Lilly stock costs EUR 1,049.90 while volume is 75.4 percent below average

Published on 10/09/2026 at 19:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eli Lilly stock costs EUR 1,049.90 on October 9, 2026 after EUR 1,040.80. Earnings follow October 29, 2026, and market value is USD 1,106.8 billion.

Key points in brief

Eli Lilly stock was at EUR 1,049.90 at Lang & Schwarz on October 9, 2026, plus 0.87 percent versus EUR 1,040.80.
Trading volume stood 75.4 percent below the average, while the USD 1,440.00 Cantor Fitzgerald target was 22.5 percent above the NYSE price.
The next earnings call is scheduled for October 29, 2026, and market capitalization was USD 1,106.8 billion.

Bauhaus-Poster mit geometrischen Formen und dem Wort PHARMA in Rot und Blau — Bauhaus-Poster mit geometrischen Formen repräsentiert Eli Lilly and Company, ISIN US5324571083, im Pharmasektor gestalterisch, Illustration mit AI erstellt.

Eli Lilly and Co. (ISIN US5324571083) was trading at EUR 1,049.90 at Lang & Schwarz on October 9, 2026 at 7:00 p.m. CEST, plus 0.87 percent versus the prior close of EUR 1,040.80. Trading volume was 75.4 percent below its average, making turnover the clearest short-term contrast in the quote.

After-hours price stays above close

The Lang & Schwarz price was in after-hours trading under the Xetra session model. Bid and ask levels were EUR 1,048.60 and EUR 1,051.20, respectively, while the latest quote remained EUR 9.10 above the prior close.

On the NYSE, Eli Lilly was last at USD 1,175.28 at 1:02 p.m. ET on October 9, 2026. Its 52-week range was USD 783.85 to USD 1,292.65, placing the share price 9.1 percent below the high and 49.8 percent above the low.

Valuation and analyst target

Eli Lilly's market capitalization was USD 1,106.8 billion on October 9, 2026, with a price-to-earnings ratio of 39.4 and a trailing dividend yield of 0.01 percent. The figures place the company at a much higher earnings multiple than the selected pharmaceutical peers below.

According to Markets Insider on October 8, 2026, Cantor Fitzgerald analyst Carter Gould raised the target from USD 1,410.00 to USD 1,440.00 and retained an Overweight rating. The new target lies 22.5 percent above the NYSE price of USD 1,175.28.

Comparison with peers

Eli Lilly and Co.: plus 0.87 percent, P/E 39.4, market capitalization USD 1,106.8 billion.
Pfizer Inc. (NYSE, USD): plus 1.06 percent, P/E 37.1, market capitalization USD 160.2 billion.
Novo Nordisk A/S (NYSE, USD): plus 0.54 percent, P/E 9.8, market capitalization USD 170.5 billion.

Next earnings date is October 29

Eli Lilly and Company lists its next earnings call for October 29, 2026, at 10:00 a.m. EDT. That date gives the market its next scheduled point for comparing demand, margins and the company's forward outlook.

Price remains the key market marker

The combination of a EUR 1,049.90 after-hours quote, a USD 1,106.8 billion market value and a USD 1,440.00 analyst target frames the stock's current market position without combining euro and dollar price changes.

The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.